Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies.

Autor: Keller KM; Princess Máxima Center for Paediatric Oncology, Utrecht, the Netherlands., Krausert S; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany., Gopisetty A; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany., Luedtke D; Eli Lilly and Company, Indianapolis, IN, USA., Koster J; Department of Oncogenomics, Amsterdam University Medical Centre, Amsterdam, the Netherlands., Schubert NA; Princess Máxima Center for Paediatric Oncology, Utrecht, the Netherlands., Rodríguez A; Hoffman-La Roche, Basel, Switzerland., van Hooff SR; Princess Máxima Center for Paediatric Oncology, Utrecht, the Netherlands., Stichel D; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Dolman MEM; Princess Máxima Center for Paediatric Oncology, Utrecht, the Netherlands; Children's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, Australia; School of Women's and Children's Health, Faculty of Medicine, UNSW Sydney, NSW Australia., Vassal G; Department of Clinical Research, Gustave Roussy, Villejuif, France., Pfister SM; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany., Caron HN; Hoffman-La Roche, Basel, Switzerland., Stancato LF; Eli Lilly and Company, Indianapolis, IN, USA., Molenaar JJ; Princess Máxima Center for Paediatric Oncology, Utrecht, the Netherlands., Jäger N; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany., Kool M; Princess Máxima Center for Paediatric Oncology, Utrecht, the Netherlands; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: m.kool@kitz-heidelberg.de.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Feb; Vol. 162, pp. 107-117. Date of Electronic Publication: 2021 Dec 25.

Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses.

Autor: Schubert NA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Schild L; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van Oirschot S; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Keller KM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Alles LK; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Vernooij L; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Nulle ME; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Dolman MEM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van den Boogaard ML; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address: j.j.molenaar@prinsesmaximacentrum.nl.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Jan; Vol. 142, pp. 1-9. Date of Electronic Publication: 2020 Nov 13.

Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.

Autor: Schmidt C; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Schubert NA; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Brabetz S; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Mack N; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Schwalm B; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Chan JA; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Selt F; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Herold-Mende C; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Witt O; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Milde T; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Pfister SM; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Korshunov A; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany., Kool M; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute and Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Section of Pediatric Brain Tumors, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Clinical Trial Center, Heidelberg, Germany; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.

Publikováno v: Neuro-oncology [Neuro Oncol] 2017 Nov 29; Vol. 19 (12), pp. 1607-1617.

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.

Autor: van Lith SA; Department of Pathology, Radboudumc, Nijmegen, The Netherlands., Navis AC; Department of Pathology, Radboudumc, Nijmegen, The Netherlands., Lenting K; Department of Pathology, Radboudumc, Nijmegen, The Netherlands., Verrijp K; Department of Pathology, Radboudumc, Nijmegen, The Netherlands., Schepens JT; Department of Cell Biology, Radboud Institute for Molecular Life Sciences, The Netherlands., Hendriks WJ; Department of Cell Biology, Radboud Institute for Molecular Life Sciences, The Netherlands., Schubert NA; Department of Pathology, Radboudumc, Nijmegen, The Netherlands., Venselaar H; Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, The Netherlands., Wevers RA; Translational Metabolic Laboratory, Department Laboratory Medicine, Radboudumc, Nijmegen, The Netherlands., van Rooij A; Translational Metabolic Laboratory, Department Laboratory Medicine, Radboudumc, Nijmegen, The Netherlands., Wesseling P; Department of Pathology, Radboudumc, Nijmegen, The Netherlands.; Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands., Molenaar RJ; Department of Cell Biology and Histology, Academic Medical Center, Amsterdam, The Netherlands., van Noorden CJ; Department of Cell Biology and Histology, Academic Medical Center, Amsterdam, The Netherlands., Pusch S; Clinical Cooperation Unit Neuropathology, German Cancer Center (DKFZ), Heidelberg, Germany., Tops B; Department of Pathology, Radboudumc, Nijmegen, The Netherlands., Leenders WP; Department of Pathology, Radboudumc, Nijmegen, The Netherlands.

Publikováno v: Scientific reports [Sci Rep] 2016 Jul 27; Vol. 6, pp. 30486. Date of Electronic Publication: 2016 Jul 27.

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs.

Autor: Chapple, Richard H., Liu, Xueying, Natarajan, Sivaraman, Alexander, Margaret I. M., Kim, Yuna, Patel, Anand G., LaFlamme, Christy W., Pan, Min, Wright, William C., Lee, Hyeong-Min, Zhang, Yinwen, Lu, Meifen, Koo, Selene C., Long, Courtney, Harper, John, Savage, Chandra, Johnson, Melissa D., Confer, Thomas, Akers, Walter J., Dyer, Michael A.

Publikováno v: Genome Biology; 6/19/2024, Vol. 25 Issue 1, p1-26, 26p